Novavax (NASDAQ: NVAX) reported Q3 EPS of ($0.12), in-line with the analyst estimate of ($0.12). Revenue for the quarter came in at $7.7 million versus the consensus estimate of $9.4 million.

For earnings history and earnings-related data on Novavax (NVAX) click here.